Modulation of Cytokine-Induced Astrocytic Endothelin-1 Production as a Possible New Approach to the Treatment of Multiple Sclerosis
Background: In the human central nervous system (CN), resting astrocytes do not visually show endothelin-1 (ET-1)-like immunoreactivity. In patients with multiple sclerosis (MS), an inflammatory disorder of the CNS, high levels of ET-1 are found in reactive astrocytes in demyelinated plaques. ET-1 m...
Main Authors: | Stéphanie Hostenbach, Miguel D’Haeseleer, Ron Kooijman, Jacques De Keyser |
---|---|
פורמט: | Article |
שפה: | English |
יצא לאור: |
Frontiers Media S.A.
2020-01-01
|
סדרה: | Frontiers in Pharmacology |
נושאים: | |
גישה מקוונת: | https://www.frontiersin.org/article/10.3389/fphar.2019.01491/full |
פריטים דומים
-
Definition, prevalence and predictive factors of benign multiple sclerosis
מאת: Tatjana Reynders, et al.
יצא לאור: (2017-06-01) -
Role of cerebral hypoperfusion in multiple sclerosis (ROCHIMS): study protocol for a proof-of-concept randomized controlled trial with bosentan
מאת: Stéphanie Hostenbach, et al.
יצא לאור: (2019-03-01) -
Astrocytic β2-adrenergic receptors and multiple sclerosis
מאת: Jacques De Keyser, et al.
יצא לאור: (2004-03-01) -
Cerebrospinal fluid inflammatory biomarkers for disease progression in Alzheimer’s disease and multiple sclerosis: a systematic review
מאת: Joke Temmerman, et al.
יצא לאור: (2023-07-01) -
Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in
מאת: Jeroen Van Schependom, et al.
יצא לאור: (2019-12-01)